Intelligence Feed event · Equity · 2026-09-30

    Staar Surgical Rallies 8% Following Stifel Upgrade to Buy and $31 Target

    Question

    Staar Surgical Rallies 8% Following Stifel Upgrade to Buy and $31 Target

    Direct answer

    Staar Surgical experienced significant upward price momentum following an upgrade by Stifel analyst Thomas Stephan. The rating was adjusted from hold to buy alongside a price target boost to $31 from $28. The positive reassessment centers on an anticipated rebound in procedural volumes for the company's implantable collamer lenses during the second half of 2026, pointing to improved underlying market demand in ophthalmic surgery.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-30
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Staar Surgical Rallies 8% Following Stifel Upgrade to Buy and $31 Target”, revision 1, evidence through 2026-09-30. https://marketontology.com/market-events/2026-09-30/staar-surgical-rallies-8-following-stifel-upgrade-to-buy-and-31-target-2761dc

    EQUITY
    Staar Surgical Rallies 8% Following Stifel Upgrade to Buy and $31 Target
    Staar Surgical experienced significant upward price momentum following an upgrade by Stifel analyst Thomas Stephan. The rating was adjusted from hold to buy alongside a price target boost to $31 from $28. The positive reassessment centers on an anticipated rebound in procedural volumes for the company's implantable collamer lenses during the second half of 2026, pointing to improved underlying market demand in ophthalmic surgery.
    STAASF
    Impact
    63
    SEP 30
    SIG
    85%
    STAASF
    Staar Surgical Rallies 8% Following Stifel Upgrade to Buy and $31 Target
    Staar Surgical experienced significant upward price momentum following an upgrade by Stifel analyst Thomas Stephan. The rating was adjusted from hold to buy alongside a price target boost to $31 from $28. The positive reassessment centers on an anticipated rebound in procedural volumes for the company's implantable collamer lenses during the second half of 2026, pointing to improved underlying market demand in ophthalmic surgery.
    → Upward revisions to second-half 2026 implantable lens unit volume drive multiple expansion and equity rerating in STAA.
    Impact
    Staar Surgical experienced significant upward price momentum following an upgrade by Stifel analyst Thomas Stephan. The rating was adjusted from hold to buy alongside a price target boost to $31 from $28. The positive reassessment centers on an anticipated rebound in procedural volumes for the company's implantable collamer lenses during the second half of 2026, pointing to improved underlying market demand in ophthalmic surgery.
    Affected
    STAASF
    Transmission
    Upward revisions to second-half 2026 implantable lens unit volume drive multiple expansion and equity rerating in STAA.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    STAAsell-side target upward revision driving momentum buyingUp1-5dStifel upgraded STAA to buy and raised PT to $31.
    SFequity research publish actionWatch1-5dStifel initiated the research upgrade on STAA.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    STAAUpdisagreed22.61 2026-09-30-1.02%-1.11%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month